The DPYD Test by Tempus is an advanced assay designed to identify genetic variants in the dihydropyrimidine dehydrogenase gene, which plays a critical role in metabolizing chemotherapy drugs like 5-FU and capecitabine. This test is vital for assessing patient risk for severe toxicity and adverse reactions to these medications, ensuring safer treatment plans. By targeting key genetic points, the DPYD Test offers clinicians critical insights into individual patient susceptibility, marking a significant advancement in personalized chemotherapy regimens.
